Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Amicus Therapeutics (NASDAQ:FOLD) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Amicus and see what CAPS investors are saying about the stock right now.

Amicus facts

Headquarters (founded)

Cranbury, N.J. (2002)

Market Cap

$282.9 million

Industry

Biotechnology

Trailing-12-Month Revenue

$24.0 million

Management

Chairman/CEO John Crowley
CFO William Baird

Return on Equity (average, past 3 years)

(71.9%)

Cash/Debt

$106.2 million / $900,000

Competitors

Actelion
Genzyme
Shire (NASDAQ:SHPG)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 25% of the 80 members who have rated Amicus believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock's recent run as particularly unsustainable:

Amicus is showing another upward kick in advance of data from Study 011 of Amigal in Fabry's disease, with topline results likely to be released this month. Similar upward movements earlier this year have not been sustained. I've been dubious about Amicus since 2007, when the share price declined precipitously despite the company's claims of positive results from the phase II trial of Amigal. I've never seen a complete data set from that trial, and it's difficult to understand the company's sparse press releases from that study and the subsequent extension study. A second major failure with Gaucher's disease drug Plicera didn't do much to boost my long-term faith in the company. Amicus might well report positive results from Study 011, but I don't think that will guarantee any kind of sustained positive response in the stock.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.